Pfiz­er dumps 3 projects in Q2 pipeline prun­ing; Te­va seals 12-year lease on new NJ head­quar­ters

→ Pfiz­er $PFE has added to the list of drugs be­ing culled from the in­dus­try pipeline to­day. Its list of projects and ther­a­pies that are be­ing dropped in­cludes the EU reg­is­tra­tion of Su­tent as a re­nal cell car­ci­no­ma ad­ju­vant, and two ear­ly-stage Phase I pro­grams for di­a­betes (PF-06342674) and can­cer (PF-06747775).

→ Of­fi­cial­ly putting its foot down in its new home of New Jer­sey, Te­va has signed a 12-year lease that would kick­start the over­haul of a 360,000 square-foot of­fice build­ing in Par­sip­pa­ny, NJ. “They are look­ing to move in as quick­ly as pos­si­ble,” Har­vey Rosen­blatt, whose com­pa­ny owns and man­ages the prop­er­ty, told NJ Ad­vance Me­dia. “But it is an as­tro­nom­i­cal build-out process.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER